Get Your Personalized Supplement StackSupplement Stack Quiz

Pure Cbd Extract

Also known as: CBD, Pure CBD extract, cannabidiol extract, Cannabidiol

Overview

Pure CBD extract is a concentrated form of cannabidiol, a non-psychoactive phytocannabinoid derived primarily from Cannabis sativa plants, specifically hemp varieties with very low tetrahydrocannabinol (THC) content. Unlike THC, CBD does not produce intoxicating effects or euphoria. It is widely used for its potential therapeutic benefits, which include managing symptoms associated with epilepsy, anxiety, chronic pain, and inflammation, as well as its neuroprotective properties. CBD interacts with the body's endocannabinoid system, albeit indirectly, by influencing receptor signaling and neurotransmitter release. It is commonly administered orally or topically. Research into CBD's effects is ongoing, with a moderate to advanced maturity level, particularly strong evidence for its use in certain epilepsy syndromes, and emerging but less consistent data for other conditions.

Benefits

Pure CBD extract demonstrates its strongest and most consistent benefits in the treatment of certain forms of epilepsy. Multiple randomized controlled trials (RCTs) and meta-analyses have shown significant reductions in seizure frequency in patients with treatment-resistant epilepsy syndromes, such as Dravet syndrome and Lennox-Gastaut syndrome, with clinically meaningful effect sizes. For anxiety and neuropsychiatric symptoms, there is some evidence of anxiolytic effects, though clinical trial data are limited and heterogeneous, suggesting less robust and consistent outcomes compared to epilepsy. In the context of chronic pain, evidence is inconsistent; while cannabinoids, including CBD, may offer modest pain relief, pure CBD alone often shows less robust effects than when combined with THC or other cannabinoids. Anti-inflammatory and neuroprotective effects are supported by preclinical data, but require further high-quality clinical trials to confirm. Pediatric epilepsy patients show the most consistent and significant benefits, whereas adults with chronic pain or anxiety have less definitive outcomes. For epilepsy, benefits are typically observed within weeks to months of treatment initiation.

How it works

Cannabidiol (CBD) primarily modulates the endocannabinoid system indirectly, rather than binding directly to CB1 and CB2 receptors with high affinity. Instead, it influences receptor signaling and neurotransmitter release. Beyond the endocannabinoid system, CBD interacts with other biological targets, including TRPV1 receptors, which are involved in pain and inflammation, and serotonin 5-HT1A receptors, which play a role in mood and anxiety. It also modulates intracellular calcium signaling. When administered orally, CBD has low bioavailability (approximately 6-19%) due to significant first-pass metabolism in the liver. However, lipid-based formulations can improve its absorption and overall bioavailability.

Side effects

Pure CBD extract is generally well tolerated and has a favorable safety profile in clinical trials. The most common side effects, reported in over 5% of users, include somnolence (drowsiness), diarrhea, decreased appetite, fatigue, and elevated liver enzymes. Less common side effects, occurring in 1-5% of users, may include dizziness, nausea, and rash. Serious adverse events are rare, but hepatotoxicity (liver damage) has been observed at high doses. CBD is known to inhibit cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19. This inhibition can alter the plasma levels of co-administered medications, such as antiepileptics and anticoagulants, potentially leading to increased drug concentrations and adverse effects. Therefore, caution is advised for patients with liver impairment or those taking medications metabolized by CYP450 enzymes. While pediatric use is established for epilepsy, the safety of CBD during pregnancy and breastfeeding is not well studied.

Dosage

For the treatment of epilepsy, the typical starting dosage for pure CBD extract is 5 mg/kg/day, administered orally. This dose is then gradually titrated upwards based on individual response and tolerability, often reaching 20 mg/kg/day or higher. Doses up to 50 mg/kg/day have been studied in epilepsy patients under medical supervision. For other indications, optimal dosages are less well-defined, and lower doses are generally recommended. CBD is usually administered twice daily, and taking it with food, particularly fatty meals, can significantly enhance its absorption and bioavailability. The purity and concentration of CBD can vary widely between different oral solutions, capsules, and oils, which should be considered when determining dosage. While no specific cofactors are essential, monitoring liver function and plasma levels of co-administered drugs is advised due to potential drug interactions.

FAQs

Is pure CBD extract psychoactive?

No, pure CBD extract is not psychoactive. It does not produce intoxication, euphoria, or the 'high' associated with cannabis.

How long does it take to see effects from CBD?

For epilepsy, therapeutic effects typically become noticeable within weeks to months of consistent use. For conditions like anxiety or pain, effects can be more variable and less predictable, often taking several days to weeks.

Is pure CBD extract safe for long-term use?

Long-term safety data for CBD are still accumulating, but current evidence from clinical trials suggests it is generally well-tolerated with a favorable safety profile over extended periods.

Can CBD cause addiction?

There is no evidence to suggest that pure CBD extract has addictive potential. It does not produce dependence or withdrawal symptoms commonly associated with addictive substances.

Does CBD interact with other medications?

Yes, CBD can interact with other medications, particularly those metabolized by liver enzymes CYP3A4 and CYP2C19. It's crucial to consult a healthcare professional if you are taking other medications.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC7608221/ – This systematic review and meta-analysis by Chesney et al. (2020) evaluated the safety and tolerability of CBD across multiple clinical trials, including those for epilepsy and other conditions. It concluded that CBD is generally well-tolerated, with common side effects being mild to moderate, and confirmed its efficacy in reducing seizures in epilepsy patients.
https://www.nature.com/articles/s41598-021-02770-6 – Treves et al. (2021) conducted a systematic review and meta-analysis focusing on pediatric patients with epilepsy and behavioral disorders. The study confirmed CBD's efficacy in reducing seizures in pediatric epilepsy and found an acceptable safety profile, though it noted limited data for other indications.
https://jamanetwork.com/journals/jama/fullarticle/2338251 – This systematic review and meta-analysis by Whiting et al. (2015) assessed the efficacy and safety of cannabinoids for various medical conditions, including pain and nausea. It found some evidence of benefit for cannabinoids in these areas, but noted high heterogeneity among studies and that pure CBD alone was less extensively studied compared to cannabinoid combinations.
https://www.acpjournals.org/doi/10.7326/M21-4520 – McDonagh et al. (2022) performed a systematic review on cannabinoids for chronic pain. The review indicated that products with higher THC:CBD ratios might offer modest pain relief, while pure CBD products showed less effectiveness. It also highlighted that adverse events were more frequent with THC-containing products.